Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10

MLA

Emily A. Bates, et al. “Development of a Low-Seroprevalence, Αvβ6 Integrin-Selective Virotherapy Based on Human Adenovirus Type 10.” Molecular Therapy: Oncolytics, vol. 25, no. 43–56, June 2022, pp. 43–56. EBSCOhost, https://doi.org/10.1016/j.omto.2022.03.007.

APA

Emily A. Bates, James A. Davies, Jana Váňová, Davor Nestić, Valerie S. Meniel, Sarah Koushyar, Tabitha G. Cunliffe, Rosie M. Mundy, Elise Moses, Hanni K. Uusi-Kerttula, Alexander T. Baker, David K. Cole, Dragomira Majhen, Pierre J. Rizkallah, Toby Phesse, John D. Chester, & Alan L. Parker. (2022). Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10. Molecular Therapy: Oncolytics, 25(43–56), 43–56. https://doi.org/10.1016/j.omto.2022.03.007

Chicago

Emily A. Bates, James A. Davies, Jana Váňová, Davor Nestić, Valerie S. Meniel, Sarah Koushyar, Tabitha G. Cunliffe, et al. 2022. “Development of a Low-Seroprevalence, Αvβ6 Integrin-Selective Virotherapy Based on Human Adenovirus Type 10.” Molecular Therapy: Oncolytics 25 (43–56): 43–56. doi:10.1016/j.omto.2022.03.007.